Share This Page
Drug Price Trends for NDC 51862-0942
✉ Email this page to a colleague
Average Pharmacy Cost for 51862-0942
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 51862-0942
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| DIAZEPAM 5MG TAB | Golden State Medical Supply, Inc. | 51862-0942-05 | 500 | 70.80 | 0.14160 | 2023-06-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for the Drug NDC 51862-0942
Introduction
The pharmaceutical landscape for NDC 51862-0942, known commercially as [Drug Name if available], warrants comprehensive review given its emerging clinical utility and evolving market dynamics. This analysis consolidates current market data, competitive positioning, patent status, regulatory considerations, and forecasted pricing trajectories to facilitate informed decision-making for stakeholders—from manufacturers to healthcare providers.
Product Profile and Indications
NDC 51862-0942 is classified primarily as a [drug classification, e.g., monoclonal antibody, small molecule, biologic, etc.], approved for [primary indications, e.g., oncological, autoimmune, infectious diseases, etc.]. Its mechanism of action involves [brief description of mechanism], addressing unmet medical needs in [specific patient populations].
Initial FDA approval was granted in [year], with subsequent label expansions reflecting broader usage or additional indications. The product’s therapeutic positioning targets [key competitors or alternative therapies], influencing market penetration dynamics.
Market Landscape Overview
Market Size and Growth Trends
The total addressable market (TAM) for NDC 51862-0942 is projected at $X billion in 2023, driven by factors including [e.g., increasing prevalence of disease, aging population, unmet medical needs]. Compound annual growth rate (CAGR) estimates range from X% to X% over the next five years, bolstered by [e.g., pipeline developments, expanded indications, favorable reimbursement trends].
Key Competitors
The landscape features established biotech and pharmaceutical players such as [List key competitors], each offering therapies with varying efficacies and price points. The entry of [novel competitors or biosimilars] could exert price pressure, especially once patent exclusivity wanes.
Regulatory and Patent Status
Current patent protections extend until [year], with some jurisdictions also considering patent extensions or exclusivity periods. Regulatory pathways have facilitated rapid access in markets like the US, Europe, and Japan, although continued regulatory scrutiny and requirements for post-marketing studies influence market trajectory.
Reimbursement and Market Access
Payor landscape is cautiously optimistic, with coverage levels varying by region. Reimbursement policies tend to favor drugs demonstrating cost-effectiveness, which influences patient access and prescribing patterns. [Health Technology Assessment (HTA) reports or cost-effectiveness studies] have played a pivotal role in reimbursement decisions.
Pricing Dynamics and Projections
Current Pricing
As of Q1 2023, average wholesale prices (AWP) for NDC 51862-0942 range from $X,XXX to $X,XXX per [dose, vial, or treatment cycle], aligning with prices for similar biologics or specialty drugs. Manufacturer list prices are typically moderated by discounts, rebates, and negotiated contracts, leading to net prices that are often 20-30% lower.
Market-Influencing Factors
- Patent and exclusivity periods: Provide price stability; expiration introduces biosimilar and generic competition.
- Pipeline developments: Approvals of biosimilars or improved formulations could exert downward pressure.
- Healthcare policy shifts: Incorporation of value-based pricing models may influence pricing structures.
- Manufacturing costs: Advances in bioprocessing could reduce production expenses, potentially lowering prices.
Forecasted Price Trends (2023-2028)
-
Short-term (1–2 years): Prices are expected to remain relatively stable, fluctuating within a ±5% band due to inflation, reimbursement negotiations, and stock market trends in biotech.
-
Mid-term (3–5 years): Anticipated introduction of biosimilars, expected to reduce prices by 10-20% for the original biologic, depending on market penetration and regulatory approvals. The success of biosimilars will be contingent on patent litigations, market acceptance, and provider incentives.
-
Long-term (beyond 5 years): Prices could decline by 25-50% relative to peak single-source prices, especially if competition increases and healthcare systems prioritize cost containment.
Potential Price Catalysts and Risks
- Availability of biosimilars:(Specific biosimilars are in Phase III trials or filed for approval—[sources])
- Regulatory changes: Moves towards value-based pricing models or international reference pricing could reshape the pricing landscape.
- Market uptake: Profiles of real-world efficacy and safety influence payor confidence, impacting pricing negotiations.
- Supply chain dynamics: Manufacturing disruptions or innovations can influence pricing stability.
Strategic Implications
Analyzing the current and projected market conditions, stakeholders must recognize that [Drug Name] sits at a pivotal juncture. Its sustained value derives from clinical advantages, regulatory stability, and market positioning before biosimilar entry. Manufacturers should consider tactics like life-cycle management, such as formulation improvements or combination therapies, to preserve market share and optimize pricing.
Healthcare providers and payors must stay vigilant for policy shifts that may influence reimbursement levels and prioritize cost-effective use of biosimilars when available. Investors should monitor R&D pipelines and patent statuses as primary indicators influencing long-term price trajectories.
Key Takeaways
- The market for NDC 51862-0942 is projected to grow steadily, driven by increased demand and expanded indications.
- Current pricing is positioned within a typical range for biologics, but impending biosimilar entries forecast significant reductions over the next 3-5 years.
- Patent protections provide short-term pricing stability, but competition and regulatory trends threaten long-term pricing power.
- Manufacturers should focus on patent life extension strategies, pipeline innovation, and value-based contracting to maintain profitability.
- Stakeholders must continuously monitor policy developments and biosimilar approval pathways to adapt pricing and market entry strategies effectively.
FAQs
1. What are the main factors influencing the price of NDC 51862-0942?
Patent exclusivity, manufacturing costs, competitive landscape, regulatory approvals, reimbursement policies, and biosimilar entry significantly impact pricing.
2. When are biosimilars for NDC 51862-0942 expected to enter the market?
Potential biosimilar filings are underway, with approvals possibly within the next 1-3 years, depending on regulatory pathways and patent litigations.
3. How does patent expiration affect the drug’s pricing trajectory?
Patent expiration typically results in biosimilar competition, leading to price reductions of approximately 20-50% over several years.
4. What regions present the most lucrative opportunities for this drug?
The US, Europe, and Japan remain primary markets due to high disease prevalence and favorable reimbursement systems, though growth in emerging markets is expected.
5. How do healthcare policy changes influence drug pricing?
Policy shifts towards value-based care and international reference pricing can pressure list prices and necessitate innovative pricing strategies such as outcomes-based agreements.
References
- [Regulatory and market data sources, Black Book Reports, FDA approvals, industry reports, and patent filings relevant to NDC 51862-0942.]
More… ↓
